I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

BPMC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.21%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $31,397,044.73

Blueprint Medicines Insider Trading History Chart

Blueprint Medicines Share Price & Price History

^$96.62

▲ +1.81 (1.91%)

As of 11/21/2024 05:16 PM ET

Days: 30 | 90 | 365

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Blueprint Medicines Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2024	Fouad Namouni	Insider	Sell	3,633	$89.32	$324,499.56	69,070
8/5/2024	Philina Lee	Insider	Sell	41,913	$93.19	$3,905,872.47	34,729
7/5/2024	Debra Durso-Bumpus	Insider	Sell	3,850	$111.20	$428,120.00	43,763
7/3/2024	Debra Durso-Bumpus	Insider	Sell	8,817	$111.29	$981,243.93	43,763
6/28/2024	Debra Durso-Bumpus	Insider	Sell	333	$111.15	$37,012.95	43,763
6/21/2024	Debra Durso-Bumpus	Insider	Sell	74,034	$104.19	$7,713,602.46	43,763
6/5/2024	Percy H. Carter	Insider	Sell	4,000	$105.13	$420,520.00	41,895
6/3/2024	L. Becker Hewes	Insider	Sell	4,922	$106.43	$523,848.46	31,938
5/31/2024	L. Becker Hewes	Insider	Sell	34,108	$105.91	$3,612,378.28	36,860
5/2/2024	Ariel Hurley	Insider	Sell	1,834	$103.88	$190,515.92	14,913
5/2/2024	Michael Landsittel	CFO	Sell	10,000	$105.00	$1,050,000.00	47,286
3/28/2024	Michael Landsittel	CFO	Sell	5,000	$95.00	$475,000.00	47,286
3/20/2024	Jeffrey W. Albers	Director	Sell	25,073	$87.28	$2,188,371.44	176,050
3/15/2024	Michael Landsittel	CFO	Sell	13,734	$87.78	$1,205,570.52	47,286
3/7/2024	Christina Rossi	COO	Sell	6,070	$90.69	$550,488.30	64,306
3/7/2024	Jeffrey W. Albers	Director	Sell	11,033	$90.69	$1,000,582.77	165,017
3/7/2024	Kate Haviland	CEO	Sell	12,464	$90.69	$1,130,360.16	153,177
3/7/2024	L. Becker Hewes	Insider	Sell	3,097	$90.69	$280,866.93	46,281
3/7/2024	Michael Landsittel	CFO	Sell	5,003	$90.69	$453,722.07	56,020
3/7/2024	Tracey L. Mccain	EVP	Sell	5,194	$90.69	$471,043.86	60,498
3/4/2024	Christopher K. Murray	Insider	Sell	621	$93.65	$58,156.65	36,374
2/28/2024	Christopher K. Murray	Insider	Sell	5,000	$100.00	$500,000.00	24,495
1/25/2024	Jeffrey W. Albers	Director	Sell	25,000	$81.91	$2,047,750.00	176,050
12/22/2023	Ariel Hurley	Insider	Sell	714	$90.00	$64,260.00	14,324
12/7/2023	Christopher K. Murray	Insider	Sell	5,000	$75.00	$375,000.00	24,495
12/4/2023	Christopher K. Murray	Insider	Sell	600	$71.43	$42,858.00	24,495
11/30/2023	Jeffrey W. Albers	Director	Sell	5,000	$70.55	$352,750.00	176,050
11/24/2023	Jeffrey W. Albers	Director	Sell	15,000	$67.51	$1,012,650.00	176,050
11/3/2023	Jeffrey W. Albers	Director	Sell	1,485	$60.13	$89,293.05	176,050
11/1/2023	Jeffrey W. Albers	Director	Sell	3,881	$60.02	$232,937.62	176,050
10/26/2023	Christopher K. Murray	Insider	Sell	600	$56.40	$33,840.00	25,095
10/4/2023	Fouad Namouni	Insider	Sell	3,769	$48.06	$181,138.14	62,080
9/28/2023	Jeffrey W. Albers	Director	Sell	6,898	$50.17	$346,072.66	176,050
8/25/2023	Jeffrey W. Albers	Director	Sell	10,000	$50.16	$501,600.00	176,050
6/5/2023	Percy H. Carter	Insider	Sell	2,307	$52.06	$120,102.42	38,117
3/6/2023	Christina Rossi	COO	Sell	3,059	$45.67	$139,704.53	55,376
3/6/2023	Christopher K. Murray	Insider	Sell	1,875	$45.68	$85,650.00	25,695
3/6/2023	Jeffrey W. Albers	Director	Sell	9,793	$45.67	$447,246.31	173,450
3/6/2023	Kate Haviland	CEO	Sell	6,640	$45.69	$303,381.60	125,641
3/6/2023	Michael Landsittel	CFO	Sell	3,007	$45.68	$137,359.76	48,523
3/6/2023	Tracey L. Mccain	EVP	Sell	3,322	$45.68	$151,748.96	52,666
12/5/2022	Jeffrey W. Albers	Director	Sell	20,000	$50.09	$1,001,800.00	183,243
11/3/2022	Christina Rossi	COO	Sell	533	$45.24	$24,112.92	43,435
11/3/2022	Kate Haviland	CEO	Buy	1,100	$43.98	$48,378.00	92,281
10/4/2022	Fouad Namouni	Insider	Sell	3,477	$67.30	$234,002.10	52,797
8/24/2022	Debra Durso-Bumpus	Insider	Sell	5,000	$75.11	$375,550.00	40,836
8/22/2022	Jeffrey W. Albers	Director	Sell	8,410	$70.54	$593,241.40	183,243
8/19/2022	Jeffrey W. Albers	Director	Sell	1,590	$70.02	$111,331.80	183,243
8/16/2022	Jeffrey W. Albers	Director	Sell	20,000	$68.41	$1,368,200.00	183,243
8/8/2022	Jeffrey W. Albers	Director	Sell	10,000	$70.07	$700,700.00	183,243
8/4/2022	Christopher K. Murray	SVP	Sell	2,500	$60.44	$151,100.00	21,320
6/6/2022	Percy H. Carter	Insider	Sell	1,908	$59.76	$114,022.08	28,685
4/6/2022	Jeffrey W. Albers	CEO	Sell	5,000	$70.11	$350,550.00	183,243
3/17/2022	George Demetri	Director	Sell	10	$58.56	$585.60	5,812
3/16/2022	L. Becker Hewes	Insider	Sell	2,219	$60.00	$133,140.00
3/10/2022	Ariel Hurley	Insider	Sell	2,339	$57.15	$133,673.85
3/7/2022	Ariel Hurley	Insider	Sell	256	$56.19	$14,384.64
3/3/2022	Ariel Hurley	Insider	Sell	761	$60.27	$45,865.47
3/3/2022	Mark Alan Goldberg	Director	Buy	5,000	$59.98	$299,900.00
12/15/2021	L. Becker Hewes	Insider	Sell	729	$100.00	$72,900.00
12/13/2021	Kate Haviland	COO	Sell	1,000	$98.30	$98,300.00
12/7/2021	Tracey L. Mccain	EVP	Sell	5,000	$97.30	$486,500.00

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

SEC Filings (Institutional Ownership Changes) for Blueprint Medicines (NASDAQ:BPMC)

Institutional Buying and Selling by Quarter

Blueprint Medicines Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/18/2024	Teachers Retirement System of The State of Kentucky	16,520	$1.53M	0.0%	+23.7%	0.026%
11/16/2024	Geode Capital Management LLC	1,480,187	$136.94M	0.0%	+1.4%	2.330%
11/15/2024	Barclays PLC	171,196	$15.84M	0.0%	-27.9%	0.269%
11/15/2024	Nomura Asset Management Co. Ltd.	22,557	$2.09M	0.0%	+13.8%	0.036%
11/15/2024	Y Intercept Hong Kong Ltd	2,662	$0.25M	0.0%	+27.6%	0.004%
11/15/2024	XTX Topco Ltd	2,200	$0.20M	0.0%	-60.0%	0.003%
11/15/2024	Zimmer Partners LP	21,100	$1.95M	0.0%	N/A	0.033%
11/15/2024	Castleark Management LLC	33,990	$3.14M	0.1%	-13.8%	0.054%
11/15/2024	Wellington Management Group LLP	3,964,610	$366.73M	0.1%	+22.5%	6.241%
11/15/2024	State Street Corp	2,765,702	$255.83M	0.0%	+16.2%	4.353%
11/15/2024	Quarry LP	350	$32K	0.0%	N/A	0.001%
11/15/2024	Readystate Asset Management LP	56,500	$5.23M	0.1%	N/A	0.089%
11/15/2024	Ikarian Capital LLC	85,000	$7.86M	1.1%	N/A	0.134%
11/15/2024	Jacobs Levy Equity Management Inc.	496,087	$45.89M	0.2%	+161.1%	0.781%
11/15/2024	Holocene Advisors LP	16,914	$1.57M	0.0%	-98.2%	0.027%
11/15/2024	Cinctive Capital Management LP	74,341	$6.88M	0.4%	+10.1%	0.117%
11/15/2024	Erste Asset Management GmbH	25,100	$2.32M	0.0%	N/A	0.040%
11/14/2024	Bellevue Group AG	3,200	$0.30M	0.0%	-37.3%	0.005%
11/14/2024	Edgestream Partners L.P.	56,123	$5.19M	0.2%	+443.7%	0.088%
11/14/2024	Fred Alger Management LLC	33,110	$3.06M	0.0%	-31.9%	0.052%
11/14/2024	Eventide Asset Management LLC	348,704	$32.26M	0.6%	+50.5%	0.549%
11/14/2024	Verition Fund Management LLC	9,759	$0.90M	0.0%	+77.5%	0.015%
11/14/2024	Captrust Financial Advisors	17,904	$1.66M	0.0%	+3.4%	0.028%
11/14/2024	Martingale Asset Management L P	15,603	$1.44M	0.0%	+7.6%	0.025%
11/14/2024	Alkeon Capital Management LLC	718,928	$66.50M	0.1%	-19.6%	1.132%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	227,911	$21.08M	0.0%	-24.5%	0.359%
11/14/2024	Ally Bridge Group NY LLC	106,080	$9.81M	5.3%	+40.2%	0.167%
11/14/2024	Zurcher Kantonalbank Zurich Cantonalbank	13,613	$1.26M	0.0%	-1.3%	0.021%
11/14/2024	Blueshift Asset Management LLC	2,998	$0.28M	0.1%	N/A	0.005%
11/13/2024	Quantbot Technologies LP	1,164	$0.11M	0.0%	N/A	0.002%
11/13/2024	FMR LLC	4,516,771	$417.80M	0.0%	-6.6%	7.110%
11/13/2024	The Manufacturers Life Insurance Company	149,996	$13.88M	0.0%	-11.1%	0.236%
11/13/2024	Bank of Montreal Can	68,562	$6.35M	0.0%	-0.7%	0.108%
11/13/2024	Fisher Asset Management LLC	335,350	$31.02M	0.0%	-0.2%	0.528%
11/12/2024	Pitcairn Co.	10,315	$0.95M	0.1%	+127.6%	0.016%
11/12/2024	Algert Global LLC	92,236	$8.53M	0.2%	+40.7%	0.145%
11/12/2024	Citigroup Inc.	143,441	$13.27M	0.0%	+19.3%	0.226%
11/12/2024	Valence8 US LP	2,618	$0.24M	0.1%	N/A	0.004%
11/12/2024	Eagle Asset Management Inc.	154,652	$15.59M	0.1%	-18.1%	0.243%
11/12/2024	Charles Schwab Investment Management Inc.	597,232	$55.24M	0.0%	+9.3%	0.940%
11/12/2024	Massachusetts Financial Services Co. MA	252,236	$23.33M	0.0%	+48.8%	0.397%
11/9/2024	Intech Investment Management LLC	18,511	$1.71M	0.0%	N/A	0.029%
11/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	69,887	$6.47M	0.0%	N/A	0.110%
11/8/2024	Advisors Asset Management Inc.	5,054	$0.47M	0.0%	+17.6%	0.008%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	5,132	$0.48M	0.0%	N/A	0.008%
11/8/2024	Segall Bryant & Hamill LLC	141,622	$13.10M	0.2%	+11.6%	0.223%
11/7/2024	Pathstone Holdings LLC	20,131	$1.86M	0.0%	-9.4%	0.032%
11/7/2024	First Turn Management LLC	178,929	$16.55M	2.6%	-3.2%	0.282%
11/7/2024	Quest Partners LLC	1,552	$0.14M	0.0%	-7.1%	0.002%
11/7/2024	Swiss National Bank	116,200	$10.75M	0.0%	+1.6%	0.183%
11/7/2024	S&CO Inc.	10,000	$0.93M	0.1%	+49.3%	0.016%
11/6/2024	Mutual of America Capital Management LLC	32,144	$2.97M	0.0%	-0.9%	0.051%
11/5/2024	Victory Capital Management Inc.	190,361	$17.61M	0.0%	-28.2%	0.300%
11/5/2024	Prime Capital Investment Advisors LLC	3,464	$0.32M	0.0%	-65.2%	0.005%
11/5/2024	Entropy Technologies LP	10,800	$1M	0.1%	N/A	0.017%
11/4/2024	Los Angeles Capital Management LLC	11,179	$1.03M	0.0%	-22.6%	0.018%
11/4/2024	State of New Jersey Common Pension Fund D	22,846	$2.11M	0.0%	-5.6%	0.036%
11/2/2024	Covestor Ltd	598	$55K	0.0%	+206.7%	0.001%
10/31/2024	Principal Financial Group Inc.	11,038	$1.02M	0.0%	-81.0%	0.018%
10/31/2024	M&G PLC	97,861	$9.10M	0.0%	N/A	0.156%
10/29/2024	Emerald Advisers LLC	375,866	$34.77M	1.4%	+10.2%	0.600%
10/29/2024	Van ECK Associates Corp	753	$64K	0.0%	-32.5%	0.001%
10/29/2024	Emerald Mutual Fund Advisers Trust	288,540	$26.69M	1.4%	+3.7%	0.461%
10/28/2024	Oak Ridge Investments LLC	15,135	$1.40M	0.1%	-3.9%	0.024%
10/28/2024	US Bancorp DE	11,971	$1.11M	0.0%	+147.6%	0.019%
10/25/2024	China Universal Asset Management Co. Ltd.	12,183	$1.13M	0.1%	+65.6%	0.019%
10/25/2024	Pallas Capital Advisors LLC	5,657	$0.52M	0.0%	+3.2%	0.009%
10/24/2024	Nisa Investment Advisors LLC	1,893	$0.18M	0.0%	-7.3%	0.003%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	2,291	$0.21M	0.0%	+22.6%	0.004%
10/23/2024	Mraz Amerine & Associates Inc.	5,781	$0.54M	0.1%	-2.8%	0.009%
10/23/2024	Values First Advisors Inc.	1,315	$0.12M	0.1%	N/A	0.002%
10/23/2024	Assenagon Asset Management S.A.	100,633	$9.31M	0.0%	-39.1%	0.161%
10/19/2024	Allspring Global Investments Holdings LLC	3,206	$0.30M	0.0%	+40.7%	0.005%
10/16/2024	Teamwork Financial Advisors LLC	2,700	$0.25M	0.0%	N/A	0.004%
10/15/2024	NBC Securities Inc.	2,725	$0.25M	0.0%	+748.9%	0.004%
10/11/2024	Creative Planning	13,194	$1.22M	0.0%	+6.8%	0.021%
10/10/2024	Essex Investment Management Co. LLC	35,461	$3.28M	0.6%	N/A	0.057%
10/10/2024	Exchange Traded Concepts LLC	2,031	$0.19M	0.0%	-19.9%	0.003%
10/9/2024	Clarus Wealth Advisors	2,590	$0.23M	0.1%	+8.6%	0.004%
10/8/2024	CWM LLC	1,870	$0.17M	0.0%	+69.2%	0.003%
10/7/2024	Diversified Trust Co	15,676	$1.45M	0.0%	-1.5%	0.025%
10/3/2024	SG Americas Securities LLC	2,521	$0.23M	0.0%	-88.4%	0.004%
8/27/2024	Clearbridge Investments LLC	220,980	$23.82M	0.0%	N/A	0.353%
8/27/2024	Dana Investment Advisors Inc.	14,744	$1.59M	0.1%	+8.2%	0.024%
8/20/2024	Novo Holdings A S	175,000	$18.86M	0.9%	-51.2%	0.279%
8/16/2024	Creative Planning	12,351	$1.33M	0.0%	+27.1%	0.020%
8/16/2024	Algert Global LLC	65,540	$7.06M	0.2%	+81.0%	0.105%
8/16/2024	Driehaus Capital Management LLC	358,255	$38.61M	0.4%	+101.0%	0.572%
8/15/2024	Susquehanna Portfolio Strategies LLC	40,277	$4.34M	0.2%	-58.8%	0.064%
8/15/2024	Mackenzie Financial Corp	4,885	$0.53M	0.0%	+5.2%	0.008%
8/15/2024	The Manufacturers Life Insurance Company	168,759	$18.19M	0.0%	-8.4%	0.270%
8/15/2024	Millennium Management LLC	627,626	$67.65M	0.0%	+540.0%	1.002%
8/15/2024	AQR Capital Management LLC	78,103	$8.42M	0.0%	+30.2%	0.125%
8/15/2024	Alpha DNA Investment Management LLC	3,879	$0.42M	0.2%	N/A	0.006%
8/15/2024	Point72 Europe London LLP	13,569	$1.46M	0.1%	N/A	0.022%
8/15/2024	Point72 Hong Kong Ltd	3,339	$0.36M	0.0%	N/A	0.005%
8/14/2024	Fred Alger Management LLC	48,588	$5.24M	0.0%	+187.3%	0.078%
8/14/2024	Point72 Asset Management L.P.	501,581	$54.06M	0.1%	+79.3%	0.792%
8/14/2024	Marshall Wace LLP	351,756	$37.91M	0.1%	+52.7%	0.562%
8/14/2024	Xponance Inc.	4,174	$0.45M	0.0%	+8.2%	0.007%

Data available starting January 2016

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $96.62

$93.00

$98.13

50 Day Range

MA: $90.00

$82.47

$101.39

52 Week Range

Now: $96.62

$65.68

$121.90

Volume

778,918 shs

Average Volume

692,850 shs

Market Capitalization

$6.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Who are the company insiders with the largest holdings of Blueprint Medicines?: Blueprint Medicines' top insider investors include:
Jeffrey W Albers (Director)
Kate Haviland (CEO)
Fouad Namouni (Insider)
Christina Rossi (COO)
Tracey L Mccain (EVP)
Michael Landsittel (CFO)
L Becker Hewes (Insider)
Debra Durso-Bumpus (Insider)
Percy H Carter (Insider)
Christopher K Murray (Insider)
Philina Lee (Insider)
Ariel Hurley (Insider)
Learn More about top insider investors at Blueprint Medicines.
Who are the major institutional investors of Blueprint Medicines?: Blueprint Medicines' top institutional investors include:
FMR LLC — 7.11%
Wellington Management Group LLP — 6.24%
State Street Corp — 4.35%
Geode Capital Management LLC — 2.33%
Alkeon Capital Management LLC — 1.13%
Charles Schwab Investment Management Inc. — 0.94%
Learn More about top institutional investors of Blueprint Medicines stock.
Which major investors are selling Blueprint Medicines stock?: In the previous quarter, BPMC stock was sold by these institutional investors:
Holocene Advisors LP
FMR LLC
Alkeon Capital Management LLC
Victory Capital Management Inc.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Barclays PLC
Assenagon Asset Management S.A.
Principal Financial Group Inc.
Within the last year, company insiders that have sold Blueprint Medicines company stock include:
Jeffrey W Albers (Director)
Kate Haviland (CEO)
Fouad Namouni (Insider)
Christina Rossi (COO)
Tracey L Mccain (EVP)
Michael Landsittel (CFO)
L Becker Hewes (Insider)
Debra Durso-Bumpus (Insider)
Percy H Carter (Insider)
Christopher K Murray (Insider)
Philina Lee (Insider)
Ariel Hurley (Insider)
Learn More investors selling Blueprint Medicines stock.
Which major investors are buying Blueprint Medicines stock?: During the last quarter, BPMC stock was bought by institutional investors including:
Wellington Management Group LLP
State Street Corp
Jacobs Levy Equity Management Inc.
Eventide Asset Management LLC
M&G PLC
Ikarian Capital LLC
Massachusetts Financial Services Co. MA
BNP PARIBAS ASSET MANAGEMENT Holding S.A.